Elosulfase

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

Growth Patterns in MPS IVA and MPS IIIA: A Longitudinal Single-Center Study.

Growth Patterns in MPS IVA and MPS IIIA: A Longitudinal Single-Center Study.

Journal: Journal of clinical medicine

Published: April 19, 2026

Long-term Natural History and Elosulfase Alfa Treatment for Mucopolysaccharidosis Type IVA: A Single-Center Study in the Czech Republic.

Long-term Natural History and Elosulfase Alfa Treatment for Mucopolysaccharidosis Type IVA: A Single-Center Study in the Czech Republic.

Journal: Research square

Published: April 03, 2026

Long-term follow-up and response to elosulfase alfa in mucopolysaccharidosis type IVA: a single-center cohort from the Czech Republic.

Long-term follow-up and response to elosulfase alfa in mucopolysaccharidosis type IVA: a single-center cohort from the Czech Republic.

Journal: Orphanet journal of rare diseases

Published: March 04, 2026

Early Versus Late Enzyme Replacement Therapy in Siblings With Morquio A Syndrome: Insights Into Therapeutic Timing.

Early Versus Late Enzyme Replacement Therapy in Siblings With Morquio A Syndrome: Insights Into Therapeutic Timing.

Journal: JIMD reports

Published: February 14, 2026

Phenotypes of Elosulfase Alfa-Induced Immediate Hypersensitivity Reactions and Long-term Outcomes of Desensitization in Mucopolysaccharidosis IVA.

Phenotypes of Elosulfase Alfa-Induced Immediate Hypersensitivity Reactions and Long-term Outcomes of Desensitization in Mucopolysaccharidosis IVA.

Journal: International archives of allergy and immunology

Published: January 14, 2026

Clinical expert opinion on the role of elosulfase alfa in non-ambulatory individuals with Morquio A syndrome.

Clinical expert opinion on the role of elosulfase alfa in non-ambulatory individuals with Morquio A syndrome.

Journal: Molecular genetics and metabolism reports

Published: October 14, 2025

Recent advances in mucopolysaccharidosis IVA treatment.

Recent advances in mucopolysaccharidosis IVA treatment.

Journal: Orphanet journal of rare diseases

Published: June 05, 2025

Long-term outcomes of elosulfase alfa enzyme replacement therapy in adults with MPS IVA: a sub-analysis of the Morquio A Registry Study (MARS).

Long-term outcomes of elosulfase alfa enzyme replacement therapy in adults with MPS IVA: a sub-analysis of the Morquio A Registry Study (MARS).

Journal: Orphanet journal of rare diseases

Published: April 30, 2025

Exploring Multivalent Architectures for Binding and Stabilization of N-Acetylgalactosamine 6-Sulfatase.

Exploring Multivalent Architectures for Binding and Stabilization of N-Acetylgalactosamine 6-Sulfatase.

Journal: Molecules (Basel, Switzerland)

Published: March 31, 2025

Real-world treatment with elosulfase alfa in patients with MPS IVA is associated with improved endurance over time.

Real-world treatment with elosulfase alfa in patients with MPS IVA is associated with improved endurance over time.

Journal: Genetics in medicine open

Published: November 08, 2024

Efficacy of different treatment strategies in patients with mucopolysaccharidosis: a systematic review and network meta-analysis of randomized controlled trials.

Efficacy of different treatment strategies in patients with mucopolysaccharidosis: a systematic review and network meta-analysis of randomized controlled trials.

Journal: Orphanet journal of rare diseases

Published: October 15, 2024

Long-term outcomes of enzyme replacement therapy from a large cohort of Korean patients with mucopolysaccharidosis IVA (Morquio A syndrome).

Long-term outcomes of enzyme replacement therapy from a large cohort of Korean patients with mucopolysaccharidosis IVA (Morquio A syndrome).

Journal: Molecular genetics and metabolism reports

Published: September 25, 2024

Showing 1-12 of 78

Last Updated: 09/26/2026